Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01756-2/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_infocusoncology_esmo24&_hsenc=p2ANqtz-_jRPbPyqWF5xDWpi-cSnrsXo3oGaeZjhSNrSFZGo79u75kA96NSlfFw99AAD3GijrpAmVwfT_ADxmgoV7Yvz8FeYShrQ&_hsmi=325179166&utm_content=325179166&utm_source=hs_email